NCT04893798已完成1 期
A PHASE 1, RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO COMPARE THE PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF MEDROXYPROGESTERONE ACETATE IN HEALTHY FEMALE PARTICIPANTS FOLLOWING SUBCUTANEOUS INJECTION OF SAYANA PRESS IN THE UPPER ARM RELATIVE TO ANTERIOR THIGH AND ABDOMEN
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 67
- 试验地点
- 2
- 主要终点
- Serum Trough Concentration (Ctrough) of Medroxyprogesterone
研究概览
简要总结
The purpose of the study is to compare the pharmacokinetics and relative bioavailability of medroxyprogesterone in healthy female participants following subcutaneous injection of Sayana Press into the upper arm versus anterior thigh and abdomen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Pre-menopausal female participants, 18 to 45 years of age, inclusive, at the time of signing the ICD who are at low risk of pregnancy
- •Participants who have a regular menstrual cycle (between 21 and 42 days in length).
- •No previous injection of depot MPA for 1 year prior to enrollment.
- •BMI of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb).
排除标准
- •History of abnormal cervical cytology within the last 3 years that has not been adequately treated (at least 2 subsequent normal smears). However, ASCUS is permitted in this study.
- •Known or suspected malignancy of the breast or genital organs.
- •Known with metabolic bone disease.
- •Undiagnosed abnormal genital bleeding.
- •Known or suspected pregnancy; or nursing females.
- •History of febrile illness within 5 days prior to the first dose.
- •Participant with active thrombophlebitis or whose medical history suggests that they may be at increased risk for osteoporosis, thromboembolic disease or cerebral vascular disease.
- •Use of prescription or nonprescription drugs, vitamins, herbal preparations and dietary supplements capable of inducing hepatic metabolism (eg, barbiturates, rifampicin, carbamazepine or St John's Wort) or any medication known to be a
- •cytochrome P450 inhibitor within 30 days (or 5 half-lives of the substance, whichever is longer) of enrollment in the study
- •Use of hormonal contraception (including hormone releasing intrauterine device) within the last 3 months (and should have resumed regular menstruation).
- •Baseline 12-lead ECG that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, baseline QTc interval >450 msec, complete LBBB, signs of an acute or indeterminate-age myocardial infarction, ST-T interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the baseline uncorrected QT interval is >450 msec, this interval should be rate-corrected using the Fridericia method and the resulting QTcF should be used for decision
- •making and reporting. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility. Computer-interpreted ECGs should be overread by a physician experienced in reading ECGs before excluding participants.
结局指标
主要结局
Serum Trough Concentration (Ctrough) of Medroxyprogesterone
时间窗: Day 92 post dose
Area under the curve from time zero to end of dosing interval (AUCtau)
时间窗: pre-dose, up to 92 days post dose
Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone
时间窗: pre-dose, up to 92 days post dose
次要结局
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs(baseline, up to 150 days post dose or until study completion, whichever is longer)
- Serum Progesterone Level(pre-dose, up to 99 days post dose)
- Serum Luteinizing Hormone (LH) Level(pre-dose, up to 99 days post dose)
- Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)(Informed consent document to 150 days post dose or until study completion, whichever is longer.)
- Serum Estradiol Level(pre-dose, up tp 99 days post dose)
- Serum Follicle-Stimulating Hormone (FSH) Level(pre-dose, up to 99 days post dose)
- Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities(Screening, Day 1, up to 150 days post dose or until study completion, whichever is longer)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KBioavailability of ASP015KPharmacokinetics of ASP015KHealthy SubjectsNCT01486017Astellas Pharma Inc30
已完成
1 期
Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy AdultsTumorNCT04472650BeiGene26
已完成
1 期
A Study to Assess the Absolute Bioavailability and Pharmacokinetics of Simeprevir (TMC435) Administered as Single Oral Doses of TMC435 and an Intravenous Microdose of [3H]-TMC435 in Healthy Male PatientsHealthy Male ParticipantsNCT01707342Janssen R&D Ireland6
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s of Escitalopram Oxalate Tablets Under Fed ConditionHealthyNCT01996475Torrent Pharmaceuticals Limited
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Montelukast Sodium 10mg Tablet Under Fasted ConditionsHealthyNCT01928056Torrent Pharmaceuticals Limited